Australia's most trusted
source of pharma news
Saturday, 21 December 2024
Posted 19 December 2024 AM
The PBAC has revealed the 16 medicines which companies hoped would be considered for reimbursement in March but were controversially booted to an additional meeting in May due to evaluation capacity constraints.
Released yesterday afternoon, the agenda for the May meeting to be held between 9-10 May details 10 change to listing submissions, six new PBS listing submissions, and one new NIP listing.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.